KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Palvella Therapeutics (PVLA) Profit After Tax: 2013-2024

Historic Profit After Tax for Palvella Therapeutics (PVLA) over the last 11 years, with Dec 2024 value amounting to -$4.0 million.

  • Palvella Therapeutics' Profit After Tax fell 110.21% to -$4.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$17.4 million, marking a year-over-year decrease of 193.27%. This contributed to the annual value of -$17.4 million for FY2024, which is 193.27% down from last year.
  • As of Q4 2024, Palvella Therapeutics' Profit After Tax stood at -$4.0 million, which was up 41.68% from -$6.8 million recorded in Q3 2024.
  • Palvella Therapeutics' Profit After Tax's 5-year high stood at $38.7 million during Q4 2023, with a 5-year trough of -$16.5 million in Q3 2021.
  • Its 3-year average for Profit After Tax is -$2.7 million, with a median of -$5.9 million in 2022.
  • Its Profit After Tax has fluctuated over the past 5 years, first tumbled by 1,695.51% in 2020, then spiked by 576.20% in 2023.
  • Over the past 5 years, Palvella Therapeutics' Profit After Tax (Quarterly) stood at -$14.4 million in 2020, then surged by 33.81% to -$9.5 million in 2021, then climbed by 14.76% to -$8.1 million in 2022, then spiked by 576.20% to $38.7 million in 2023, then plummeted by 110.21% to -$4.0 million in 2024.
  • Its Profit After Tax was -$4.0 million in Q4 2024, compared to -$6.8 million in Q3 2024 and -$4.2 million in Q2 2024.